Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial

Peter F. Schnatz, Xuezhi Jiang, Sharon Vila-Wright, Aaron K. Aragaki, Matthew Nudy, David M. O'Sullivan, Rebecca Jackson, Erin Leblanc, Jennifer G. Robinson, James M. Shikany, Catherine R. Womack, Lisa W. Martin, Marian L. Neuhouser, Mara Z. Vitolins, Yiqing Song, Stephen Kritchevsky, Joann E. Manson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVE: The objective of this study was to evaluate whether increased serum 25-hydroxyvitamin D3 (25OHD3) concentrations, in response to calcium/vitamin D (CaD) supplementation, are associated with improved lipids in postmenopausal women. METHODS: The parent trial was a double-blind, randomized, placebo-controlled, parallel-group trial designed to test the effects of CaD supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily) versus placebo in postmenopausal women. Women from the general community, including multiple sites in the United States, were enrolled between 1993 and 1998. This cohort included 300 white, 200 African-American, and 100 Hispanic participants who were randomly selected from the Women's Health Initiative CaD trial. Serum 25OHD3 and lipid (fasting plasma triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], and calculated low-density lipoprotein cholesterol [LDL-C]) levels were assessed before and after CaD randomization. RESULTS: There was a 38% increase in mean serum 25OHD3 concentrations after 2 years (95% CI, 1.29-1.47, P < 0.001) for women randomized to CaD (24.3 ng/mL postrandomization mean) compared with placebo (18.2 ng/mL). Women randomized to CaD had a 4.46-mg/dL mean decrease in LDL-C (P = 0.03). Higher concentrations of 25OHD3 were associated with higher HDL-C levels (P = 0.003), along with lower LDL-C and TG levels (P = 0.02 and P < 0.001, respectively). CONCLUSIONS: Supplemental CaD significantly increases 25OHD3 concentrations and decreases LDL-C. Women with higher 25OHD3 concentrations have more favorable lipid profiles, including increased HDL-C, lower LDL-C, and lower TG. These results support the hypothesis that higher concentrations of 25OHD3, in response to CaD supplementation, are associated with improved LDL-C.

Original languageEnglish (US)
Pages (from-to)823-833
Number of pages11
JournalMenopause
Volume21
Issue number8
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Women's Health
Vitamin D
Cholesterol
Calcium
Serum
LDL Cholesterol
HDL Cholesterol
Placebos
Lipids
Triglycerides
Calcifediol
25-hydroxyvitamin D
Cholecalciferol
Random Allocation
Hispanic Americans
African Americans
Fasting

Keywords

  • Cholesterol
  • Coronary artery disease
  • Low-density lipoprotein cholesterol
  • Menopause
  • Vitamin D

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. / Schnatz, Peter F.; Jiang, Xuezhi; Vila-Wright, Sharon; Aragaki, Aaron K.; Nudy, Matthew; O'Sullivan, David M.; Jackson, Rebecca; Leblanc, Erin; Robinson, Jennifer G.; Shikany, James M.; Womack, Catherine R.; Martin, Lisa W.; Neuhouser, Marian L.; Vitolins, Mara Z.; Song, Yiqing; Kritchevsky, Stephen; Manson, Joann E.

In: Menopause, Vol. 21, No. 8, 01.01.2014, p. 823-833.

Research output: Contribution to journalArticle

Schnatz, PF, Jiang, X, Vila-Wright, S, Aragaki, AK, Nudy, M, O'Sullivan, DM, Jackson, R, Leblanc, E, Robinson, JG, Shikany, JM, Womack, CR, Martin, LW, Neuhouser, ML, Vitolins, MZ, Song, Y, Kritchevsky, S & Manson, JE 2014, 'Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial', Menopause, vol. 21, no. 8, pp. 823-833. https://doi.org/10.1097/GME.0000000000000188
Schnatz, Peter F. ; Jiang, Xuezhi ; Vila-Wright, Sharon ; Aragaki, Aaron K. ; Nudy, Matthew ; O'Sullivan, David M. ; Jackson, Rebecca ; Leblanc, Erin ; Robinson, Jennifer G. ; Shikany, James M. ; Womack, Catherine R. ; Martin, Lisa W. ; Neuhouser, Marian L. ; Vitolins, Mara Z. ; Song, Yiqing ; Kritchevsky, Stephen ; Manson, Joann E. / Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. In: Menopause. 2014 ; Vol. 21, No. 8. pp. 823-833.
@article{3c66ddf7ffc74442b603ac7020555a07,
title = "Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial",
abstract = "OBJECTIVE: The objective of this study was to evaluate whether increased serum 25-hydroxyvitamin D3 (25OHD3) concentrations, in response to calcium/vitamin D (CaD) supplementation, are associated with improved lipids in postmenopausal women. METHODS: The parent trial was a double-blind, randomized, placebo-controlled, parallel-group trial designed to test the effects of CaD supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily) versus placebo in postmenopausal women. Women from the general community, including multiple sites in the United States, were enrolled between 1993 and 1998. This cohort included 300 white, 200 African-American, and 100 Hispanic participants who were randomly selected from the Women's Health Initiative CaD trial. Serum 25OHD3 and lipid (fasting plasma triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], and calculated low-density lipoprotein cholesterol [LDL-C]) levels were assessed before and after CaD randomization. RESULTS: There was a 38{\%} increase in mean serum 25OHD3 concentrations after 2 years (95{\%} CI, 1.29-1.47, P < 0.001) for women randomized to CaD (24.3 ng/mL postrandomization mean) compared with placebo (18.2 ng/mL). Women randomized to CaD had a 4.46-mg/dL mean decrease in LDL-C (P = 0.03). Higher concentrations of 25OHD3 were associated with higher HDL-C levels (P = 0.003), along with lower LDL-C and TG levels (P = 0.02 and P < 0.001, respectively). CONCLUSIONS: Supplemental CaD significantly increases 25OHD3 concentrations and decreases LDL-C. Women with higher 25OHD3 concentrations have more favorable lipid profiles, including increased HDL-C, lower LDL-C, and lower TG. These results support the hypothesis that higher concentrations of 25OHD3, in response to CaD supplementation, are associated with improved LDL-C.",
keywords = "Cholesterol, Coronary artery disease, Low-density lipoprotein cholesterol, Menopause, Vitamin D",
author = "Schnatz, {Peter F.} and Xuezhi Jiang and Sharon Vila-Wright and Aragaki, {Aaron K.} and Matthew Nudy and O'Sullivan, {David M.} and Rebecca Jackson and Erin Leblanc and Robinson, {Jennifer G.} and Shikany, {James M.} and Womack, {Catherine R.} and Martin, {Lisa W.} and Neuhouser, {Marian L.} and Vitolins, {Mara Z.} and Yiqing Song and Stephen Kritchevsky and Manson, {Joann E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/GME.0000000000000188",
language = "English (US)",
volume = "21",
pages = "823--833",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial

AU - Schnatz, Peter F.

AU - Jiang, Xuezhi

AU - Vila-Wright, Sharon

AU - Aragaki, Aaron K.

AU - Nudy, Matthew

AU - O'Sullivan, David M.

AU - Jackson, Rebecca

AU - Leblanc, Erin

AU - Robinson, Jennifer G.

AU - Shikany, James M.

AU - Womack, Catherine R.

AU - Martin, Lisa W.

AU - Neuhouser, Marian L.

AU - Vitolins, Mara Z.

AU - Song, Yiqing

AU - Kritchevsky, Stephen

AU - Manson, Joann E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - OBJECTIVE: The objective of this study was to evaluate whether increased serum 25-hydroxyvitamin D3 (25OHD3) concentrations, in response to calcium/vitamin D (CaD) supplementation, are associated with improved lipids in postmenopausal women. METHODS: The parent trial was a double-blind, randomized, placebo-controlled, parallel-group trial designed to test the effects of CaD supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily) versus placebo in postmenopausal women. Women from the general community, including multiple sites in the United States, were enrolled between 1993 and 1998. This cohort included 300 white, 200 African-American, and 100 Hispanic participants who were randomly selected from the Women's Health Initiative CaD trial. Serum 25OHD3 and lipid (fasting plasma triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], and calculated low-density lipoprotein cholesterol [LDL-C]) levels were assessed before and after CaD randomization. RESULTS: There was a 38% increase in mean serum 25OHD3 concentrations after 2 years (95% CI, 1.29-1.47, P < 0.001) for women randomized to CaD (24.3 ng/mL postrandomization mean) compared with placebo (18.2 ng/mL). Women randomized to CaD had a 4.46-mg/dL mean decrease in LDL-C (P = 0.03). Higher concentrations of 25OHD3 were associated with higher HDL-C levels (P = 0.003), along with lower LDL-C and TG levels (P = 0.02 and P < 0.001, respectively). CONCLUSIONS: Supplemental CaD significantly increases 25OHD3 concentrations and decreases LDL-C. Women with higher 25OHD3 concentrations have more favorable lipid profiles, including increased HDL-C, lower LDL-C, and lower TG. These results support the hypothesis that higher concentrations of 25OHD3, in response to CaD supplementation, are associated with improved LDL-C.

AB - OBJECTIVE: The objective of this study was to evaluate whether increased serum 25-hydroxyvitamin D3 (25OHD3) concentrations, in response to calcium/vitamin D (CaD) supplementation, are associated with improved lipids in postmenopausal women. METHODS: The parent trial was a double-blind, randomized, placebo-controlled, parallel-group trial designed to test the effects of CaD supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily) versus placebo in postmenopausal women. Women from the general community, including multiple sites in the United States, were enrolled between 1993 and 1998. This cohort included 300 white, 200 African-American, and 100 Hispanic participants who were randomly selected from the Women's Health Initiative CaD trial. Serum 25OHD3 and lipid (fasting plasma triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], and calculated low-density lipoprotein cholesterol [LDL-C]) levels were assessed before and after CaD randomization. RESULTS: There was a 38% increase in mean serum 25OHD3 concentrations after 2 years (95% CI, 1.29-1.47, P < 0.001) for women randomized to CaD (24.3 ng/mL postrandomization mean) compared with placebo (18.2 ng/mL). Women randomized to CaD had a 4.46-mg/dL mean decrease in LDL-C (P = 0.03). Higher concentrations of 25OHD3 were associated with higher HDL-C levels (P = 0.003), along with lower LDL-C and TG levels (P = 0.02 and P < 0.001, respectively). CONCLUSIONS: Supplemental CaD significantly increases 25OHD3 concentrations and decreases LDL-C. Women with higher 25OHD3 concentrations have more favorable lipid profiles, including increased HDL-C, lower LDL-C, and lower TG. These results support the hypothesis that higher concentrations of 25OHD3, in response to CaD supplementation, are associated with improved LDL-C.

KW - Cholesterol

KW - Coronary artery disease

KW - Low-density lipoprotein cholesterol

KW - Menopause

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84905020625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905020625&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000188

DO - 10.1097/GME.0000000000000188

M3 - Article

C2 - 24594863

AN - SCOPUS:84905020625

VL - 21

SP - 823

EP - 833

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 8

ER -